Biologicals

Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects.

Authors: Eustachio Nettis, Lucia Masciopinto, Elisabetta Di Leo, Nicola De Candia, Marcello Albanesi, Danilo Di Bona, Nicola Quaranta and Luigi Macchia

Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis

Asthma is a chronic disease characterized by airway hyperresponsiveness, inflammation and mucus production. In Type 2 asthma, two phenotypic components are often co-expressed (eosinophilic and allergic). Eleva...

Authors: Giorgio Walter Canonica, Francesco Blasi, Nunzio Crimi, Pierluigi Paggiaro, Alberto Papi, Francesca Fanelli, Annalisa Stassaldi and Gianluca Furneri

Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab

Systemic reactions (SR) to venom immunotherapy (VIT) are rare but may occur, with a rate significantly higher for honeybee than for vespid VIT. In patients with repeated SRs to VIT it is difficult to reach the...

Authors: Elisa Boni, Cristoforo Incorvaia and Marina Mauro

Rituximab in refractory sarcoidosis: a single centre experience

Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune s...

Authors: Francesco Cinetto, Nicolò Compagno, Riccardo Scarpa, Giacomo Malipiero and Carlo Agostini

European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars

Authors: Carlo Agostini, Giorgio Walter Canonica and Enrico Maggi